DB-1311/BNT324 Produces Responses in Cervical Cancer and PROC | OncLive The novel ADC DB-1311/BNT324 was effective in cervical cancer and PROC, regardless of prior treatment or histology

🧬 DB-1311 (BNT324)—a B7-H3–targeting antibody-drug conjugate—demonstrated encouraging responses in cervical cancer and PROC, with manageable safety in early-phase data. 📊
Read more ➡️ www.onclive.com/view/db-1311... #SGO2026 #gynsm #GynecologicOncology #CervicalCancer #OvarianCancer #ADC #Oncology

Shit On My Slippers Lessons on losing both dignity and control

Having committed to honesty and openness when I began this whole Substack thing, the time has come to write about shitting on my slippers. Two days in a row.

#ovariancancer

open.substack.com/pub/janehill...

GSK Mo-Rez Shrinks Tumours in 62% of Ovarian Cases GSK's Mo-Rez showed objective responses in 62% of ovarian and 67% of endometrial patients in an early trial (Apr 12, 2026), per The Guardian.

GSK Mo-Rez Shrinks Tumours in 62% of Ovarian Cases: GSK's Mo-Rez showed objective responses in 62% of ovarian and 67% of endometrial patients in an early trial (Apr 12, 2026), per The Guardian. 👈 Read full analysis #GSK #MoRez #OvarianCancer #EndometrialCancer #CancerResearch

AbbVie Ovarian Drug Shows 62.7% Response AbbVie's candidate posted a 62.7% response rate (Apr 12, 2026); durable follow-up, safety and confirmatory trials will determine regulatory and commercial impact.

AbbVie Ovarian Drug Shows 62.7% Response: AbbVie's candidate posted a 62.7% response rate (Apr 12, 2026); durable follow-up, safety and confirmatory trials will determine regulatory and commercial impact. 👈 Read full analysis #OvarianCancer #AbbVie #CancerResearch #Pharmaceuticals #ClinicalTrials

AbbVie Presents Promising Phase 2 Trial Data for ELAHERE® in Ovarian Cancer at SGO 2026 AbbVie introduced encouraging Phase 2 trial findings for ELAHERE®, a prospective treatment for platinum-sensitive ovarian cancer, showcasing a significant response rate at the SGO 2026 meeting.

AbbVie Presents Promising Phase 2 Trial Data for ELAHERE® in Ovarian Cancer at SGO 2026 #United_States #San_Juan #AbbVie #ELAHERE #OvarianCancer

Relacorilant Plus Nab-Paclitaxel Significantly Improves OS in Platinum-Resistant Ovarian Cancer | OncLive Relacorilant plus nab-paclitaxel cuts death risk by 35% and extends survival to 16 months in platinum-resistant ovarian cancer, per final ROSELLA trial data.

A new combo treatment is improving survival in platinum-resistant ovarian cancer. Relacorilant plus nab-paclitaxel is showing meaningful progress in a setting where better options are badly needed.
#OvarianCancer #CancerTreatment #ClinicalTrials #TCSC
www.onclive.com/view/relacor...

Repurposed drug may extend survival in aggressive ovarian cancer, trial shows Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant cases

A repurposed drug is showing real promise in aggressive ovarian cancer. Relacorilant, originally developed for Cushing’s syndrome, may help extend survival where treatment options are limited.
#CancerResearch #OvarianCancer #Oncology #TCSC
www.theguardian.com/society/2026...

Discover the Benefits of Ovarian Cancer Surgery in India

#OvarianCancer #CancerSurgery #AffordableCare #OncologyTreatment #HealthIndia

Read More:- www.101pressrelease.com/discover-the...

Combination therapy including relacorilant, a medicament usually used to treat excessive cortisol levels, extends survival of patients with platinum resistant ovarian cancer, phase 3 clinical trial shows.
doi.org/10.1016/S014...

#ovariancancer

Zentalis Jumps After Ovarian Cancer Trial Data Jefferies raised Zentalis' target on Apr 10, 2026; the broker increased its target ~60% and shares rallied ~28% intraday, per Investing.com — key follow-up data due within 6–12 months.

Zentalis Jumps After Ovarian Cancer Trial Data: Jefferies raised Zentalis' target on Apr 10, 2026; the broker increased its target ~60% and shares rallied ~28% intraday, per Investing.com — key follow-up data… 👈 Read full analysis #Zentalis #OvarianCancer #ClinicalTrials #Investing #Pharmaceuticals

The #OncoAlertColloquium 2026 GYN Malignancies🚨 DAY FOUR (ESGO)
Presentation by Dr. Isabelle Ray-Coquard 🇫🇷 : Year in Review Medical #OvarianCancer
WATCH HERE👉 buff.ly/P3fusql

Expanding the power of drugs used to treat liquid malignancies into solid tumours. We screened an epigenetic compound library against cell lines models of ovarian clear cell carcinoma. The BTK inhibitor ibrutinib shows promise #ovariancancer #ibrutinib 🧪 onlinelibrary.wiley.com/doi/epdf/10....

TOMORROW after the SGO 2026 Plenary Session, tune in to the NRG Oncology Podcast to hear us dive into the reported results of NRG-GY019 in #ovariancancer - Still not following us? Listen & find where to follow at http://NRGOncology.org/Podcast

This Is How Ovarian Cancer Spreads Before Doctors Can Detect A newly identified interaction between ovarian cancer cells and surrounding abdominal cells helps explain the cancer’s unusually fast and aggressive spread.

This Is How #OvarianCancer Spreads Before #Doctors Can Detect

scitechdaily.com/this-is-how-...

This is what people deal with. These people who are "tired" of #cancer patients having #gofundme to raise money for the astronomical costs of being sick with #anycancer. The post, my response. #cancerwarrior #chemo #cancersucks #ovariancancer #fuckcancer

Empowering Ovarian Cancer Immunotherapy. Aggressive ovarian cancers are deadly because they block a patient’s immune system. A new study demonstrates how this shield can be removed. #OvarianCancer #CancerResearch #Immunotherapy #MedicalBreakthrough #FutureMedicine

Click link in bio or go to https://ow.ly/HSlv50YEA5b to view this on demand education today!. #clinicaltrials #GynecologicOncology #ovariancancer #ovarianccancer #GOGPartners #GOGF

The SOROCK study is for premenopausal women (between the ages of 35 and 50) with inherited BRCA1 mutations, at least one ovary and fallopian tube, and are planning on having surgery to reduce their risk of #OvarianCancer. Learn more about this trial ➡️https://nrgoncology.org/SOROCk

Survivors reported elevated emotional & physical burden — plus greater risk to sleep & social wellness among those who experienced delays to care.

What caused those delays? Mostly insurance-related barriers: lack of coverage, payment denials, and prior authorization challenges.

#OvarianCancer

Info on ovarian cancer: malignancy of the ovary/fallopian tube causing pain, bloating, etc. Risk factors: older age, family history, genetic variants. Diagram shows liver, lymph nodes, ovaries, uterus, vagina. Stages I-IV detail cancer spread. Testing advised post-diagnosis.

Among women worldwide, #OvarianCancer is the eighth most common malignancy and cause of cancer death.

📄 This JAMA Patient Page describes ovarian cancer and its risk factors, symptoms, diagnosis, and treatment.

ja.ma/3PSOp8G

Scientists show #CSF1R correlates with poor prognosis in #OvarianCancer, and blocking it with PLX3397 enhances #paclitaxel efficacy, reprograms #macrophages, boosts #AntitumorImmunity, and reduces #angiogenesis, highlighting it as a promising target.

Read: doi.org/10.1016/j.ge...

Naturally, I’d like to state for the record there is nothing cute about #cancer.

#OvarianCancer #Stage1

#Ubiquitin-mediated stabilization of KDM5B promotes #Chemoresistance in #OvarianCancer by repressing DUSP4 and activating MAPK signaling, highlighting the KDM5B/DUSP4 axis as a #TherapeuticTarget for overcoming #Cisplatin resistance.
#STTT #OpenAccess: doi.org/10.1038/s413...

FDA Approves New Combination Therapy for Platinum-Resistant Ovarian Cancer - OCRF - OncoDaily FDA Approves New Combination Therapy for Platinum-Resistant Ovarian Cancer - OCRF / cancer, FDA, OncoDaily, Oncology, Ovarian Cancer, Ovarian Cancer Research

OCRF - FDA Approves New Combination Therapy for Platinum-Resistant Ovarian Cancer

@ocrfaustralia.bsky.social

oncodaily.com/voices/ocrf-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #OvarianCancer #CancerResearch #Ommunotherapy

Click link in bio or go to https://ow.ly/Jor850YCnmH to view this on demand education today! #clinicaltrials #GOGF #GOGPartners #GynecologicOncology #clinicaltrials #GOGPartners #GOGF #clinicaltrials #ovariancancer #IGCS2025

FDA Approves Lifyorli Combo for Platinum-Resistant Ovarian Cancer, Showing Survival Gain FDA clears Corcept’s Lifyorli with nab-paclitaxel for platinum-resistant ovarian-type cancers, the first cortisol-receptor blocker to extend survival.

FDA Approves Lifyorli Combo for Platinum-Resistant Ovarian Cancer, Showing Survival Gain

#ovariancancer #fda #chemotherapy #drugapproval #oncology

Tune in to the NRG Oncology Podcast after the SGO Session Plenary to hear us dive into the reported results of NRG-GY019 in #ovariancancer - Still not following us? Listen & find where to follow at www.NRGOncology.org/Podcast

FDA Grants Fast Track Designation to CTIM-76 for Platinum-Resistant Ovarian Cancer | OncLive CTIM-76 received fast track designation from the FDA for pretreated platinum-resistant ovarian cancer.

CTIM-76 has received fast track designation from the @FDA for pretreated platinum-resistant ovarian cancer. #oncology #gcsm #ovariancancer
www.onclive.com/view/fda-gra...

Click link in bio or go to https://ow.ly/uSip50YAYJp to view this on demand education today! #clinicaltrials #GOGF #GOGPartners #GynecologicOncology #clinicaltrials #GOGPartners #GOGF #clinicaltrials #ovariancancer #IGCS2025